RTsafe and ZAP Surgical Forge Strategic Partnership to Promote the Latest Advances in Cranial Radiosurgery

RTsafe Partnership Details

RTsafe, the leading provider of quality assurance products and services in stereotactic radiosurgery, and ZAP Surgical, the developer of the ZAP-X® Gyroscopic Radiosurgery® platform, have announced a partnership to promote advances in cranial radiosurgery. Under the terms of the agreement, RTsafe’s dosimetry phantom based on true-to-life human anatomy will be seamlessly integrated into ZAP Surgical’s existing and future global installations. This strategic alliance underscores a shared commitment to excellence, as both organizations strive to deliver optimal patient safety and value to healthcare providers and cranial radiosurgery patients alike.

The cornerstone of this partnership lies in RTsafe’s development of a specialized phantom designed specifically for use with the ZAP-X® platform that incorporates a unique vault-free design that typically eliminates the need for costly shielded treatment rooms. This new RTsafe phantom will be officially presented at the International Stereotactic Radiosurgery Society 2024 meeting, in New York City, on May 12th. This innovative solution will play a pivotal role in commissioning, training, educational initiatives, confidence building, periodic quality assurance protocols, and patient-specific quality assurance, reinforcing the state-of-the-art capabilities of ZAP-X.

Evangelos Pappas, Founder of RTsafe

“We are thrilled to join forces with ZAP Surgical in this transformative endeavour. By harnessing the power of our advanced phantom technology, we aim to elevate the standard of care in cranial radiosurgery and to highlight the unparalleled value of the ZAP-X platform”.

Renowned neurosurgeon and Founder of ZAP Surgical, Dr. John Adler

“At ZAP Surgical, we are dedicated to pushing the boundaries of innovation in the field of radiosurgery. By integrating RTsafe’s cutting-edge phantom technology into our systems, we are reinforcing our commitment to excellence and ensuring that clinicians worldwide have access to the most advanced tools for delivering exceptional patient care.” The collaboration between RTsafe and ZAP Surgical is a testament to the power of innovation and collaboration in healthcare.

SourceRTsafe

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”